SCHEMBL16334337

SCHEMBL16334337

Fc1cc(-c2cccc(OC3CCCC3)c2)cc(F)c1SCCCl

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 4/20 0.47
DHODH Q02127 3/20 0.42
FFAR1 O14842 1/20 0.36
KAT6A Q92794 1/20 0.35
ENPP2 Q13822 1/20 0.35
CETP P11597 2/20 0.34
SLC16A3 O15427 1/20 0.34
SLC16A1 P53985 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
SLC6A2 P23975 2/20 0.33
SLC6A3 Q01959 2/20 0.33
IGF1R P08069 2/20 0.33
SLC6A4 P31645 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16334682 0.88 FFAR4 (0.49) FFAR4DHODHFFAR1KAT6AENPP2
SCHEMBL16334437 0.82 FFAR4 (0.54) FFAR4DHODHFFAR1ENPP2
SCHEMBL16334426 0.80 FFAR4 (0.56) FFAR4DHODHFFAR1ENPP2SLC16A3
SCHEMBL16334862 0.80 FFAR4 (0.51) FFAR4DHODHFFAR1KAT6AENPP2
SCHEMBL1336643 0.77 FFAR4 (0.51) FFAR4DHODHFFAR1KAT6AENPP2
SCHEMBL16334746 0.76 FFAR4 (0.56) FFAR4DHODHFFAR1KAT6AENPP2
SCHEMBL28054784 0.75 SLC6A2 (0.49) FFAR4DHODHFFAR1KAT6AENPP2
SCHEMBL1336585 0.74 FFAR4 (0.47) FFAR4DHODHFFAR1KAT6APTGS1
SCHEMBL1337675 0.71 DHODH (0.49) FFAR4DHODHENPP2SLC16A3SLC16A1
SCHEMBL16334327 0.71 FFAR4 (0.47) FFAR4DHODHFFAR1ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105392777-B Biaryl derivatives as GPR120 agonists 株式会社LG化学 2020-09-22 CN disclosed
EP-3013796-B9 BIARYL DERIVATIVES AS GPR120 AGONISTS LG CHEMICAL LTD (KR) 2020-07-01 EP disclosed
EP-3628661-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG CHEM, LTD. (KR) 2020-04-01 EP disclosed
US-10221138-B2 Biaryl derivatives as GPR120 agonists LG CHEM, LTD. (KR) 2019-03-05 US disclosed
US-20160168096-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG LIFE SCIENCES LTD. (KR) 2016-06-16 US disclosed
EP-3013796-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG Life Sciences Ltd. (KR) 2016-05-04 EP disclosed
WO-2014209034-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS LG LIFE SCIENCES LTD. (KR) 2014-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168096-A1 BIARYL DERIVATIVES AS GPR120 AGONISTS GPR119, GLP1R, GIPR FFAR4 16/4885DHODH 4532/4885FFAR1 8/4885
US-10221138-B2 Biaryl derivatives as GPR120 agonists GPR119, GLP1R, GIPR FFAR4 16/4885DHODH 4532/4885FFAR1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.